Dermata Therapeutics, Inc.
- DRMA
- NASDAQ
- Biotechnology
- Dermatology Therapeutics
- Clinical-Stage Drug Development
$0.86
Today −0.01%Quote Oct 19, 2026, 08:00 PM UTC
−25.87%over the last month
Max drawdown −43.3%From 1-month high −26.5%3 months −32.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Dermata Therapeutics
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
9
Founded
2014
Market value
$3.5M
Quote Oct 19
Analyst target
$6.00
+597.8% from here
Floor
$0.85
1.2% below price
Resistance
$0.88
2.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DRMAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free